Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Blood components: current challenges.

P Rouger1

  • 1Institut national de la transfusion sanguine (INTS), 6 rue Alexandre-Cabanel, Paris cedex 15, France. prouger@ints.fr

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|April 19, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012).

Vox sanguinis·2013
Same author

Education in transfusion medicine for medical students and doctors.

Vox sanguinis·2013
Same author

[Red-blood-cell allo-immunization].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2012
Same author

[European Blood Alliance (EBA) and EuroNet TMS: what challenges for the transfusion of tomorrow?].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2011
Same author

International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report.

Vox sanguinis·2011
Same author

Blood group genotyping by high-throughput DNA analysis: application to the French panel of RBC reagents.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2010
Same journal

Catastrophic CD34+ autologous hematopoietic stem cell collection despite sustained mobilization and solutions to rescue the harvests.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Title of the study: Corrected Count Increment as a Predictor of Early Graft Dysfunction and Mortality Following Living Donor Liver Transplantation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

TLR4/MD-2 complex promotes transfusion-related acute lung injury pathogenesis through the activation of the AP-1 and NF-κB signaling pathways.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

The Strategic Utility of Cryopreserved Platelets in Outer Space.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Genotyping of Human Neutrophil Antigen-3 by High Resolution Melting Analysis in Southern Thai Blood Donors.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Transfusion rate and risk factors in hemiarthroplasty of hip: A nationwide cohort study.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
See all related articles

Labile blood products remain essential, but their usage indications vary widely across Europe and require better control. Initiatives like EuroNet-TMS and Euro

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Clinical Practice

Background:

  • Labile blood products are critical in modern medicine.
  • Current European guidelines for blood product indications show significant heterogeneity.
  • There is a need for standardized, evidence-based transfusion practices.

Purpose of the Study:

  • To highlight the continued importance of labile blood products.
  • To address the variability in transfusion indications across European countries.
  • To promote evidence-based medicine in blood product utilization.

Main Methods:

  • Analysis of European surveys on blood product usage.
  • Discussion of findings from EuroNet-TMS network meetings.
  • Review of presentations and outcomes from Euro'SAT congresses.

Related Experiment Videos

Main Results:

  • European surveys confirm widespread heterogeneity in transfusion indications.
  • Current practices for using labile blood products are not consistently controlled.
  • Collaborative networks and congresses are key to improving transfusion medicine.

Conclusions:

  • Labile blood products will remain a cornerstone of treatment.
  • Standardization of transfusion indications across Europe is necessary.
  • Evidence-based approaches, fostered by networks like EuroNet-TMS, are crucial for optimizing blood product use.